Recently, China's National Medical Products Administration (NMPA) revoked 80 drug registration certificates in one go, with over 55% belonging to foreign or joint-venture companies, sparking widespread industry debate
. Companies like Pfizer, GlaxoSmithKline (GSK), and Janssen (a subsidiary of Johnson & Johnson) have seen multiple products exit the Chinese market. Meanwhile, originator drugs failed to secure any bids in the 10th National Centralized Drug Procurement (NCMP), marking a pivotal shift. This exodus of imported drugs is no accident-it reflects profound transformations in China's pharmaceutical landscape and ushers in an unprecedented era of opportunity for domestic players.
I. Imported Drug Withdrawal: A Collision of Policy Pressures and Strategic Shifts
The retreat of imported drugs stems from two key forces: the profit squeeze from NCMP and multinational pharma's global realignment.
NCMP Squeezes Margins
China's NCMP, which aggregates nationwide hospital procurement needs to negotiate bulk discounts, has forced originator drugmakers into a dilemma: drastically cut prices to retain market share or exit entirely. For example, Merck's posaconazole injection, priced at ¥1,400 per vial, faced competition from domestic generics costing just ¥40-a 30-fold gap that made participation untenable
.
Multinationals Prioritize Innovation
With patents expiring and generics eroding market share, multinationals are redirecting resources toward high-margin, high-risk areas like oncology and rare diseases. Boehringer Ingelheim's pre-emptive withdrawal of its metformin/ertugliflozin combination from the 11th NCMP exemplifies this strategic pivot
II. Originators vs. Generics: Bridging the Quality Gap, but Trust Remains Elusive
While regulatory frameworks have narrowed the quality divide, consumer skepticism persists.
Chemical Equivalence, Process Variability
Generics and originators share identical active ingredients, but differences in crystallinity, excipients, and manufacturing processes can affect efficacy. For instance, inconsistent polymorphism in generics might alter absorption rates
.
Consistency Evaluation Validates Efficacy
Since 2016, China's Consistency Evaluation program has mandated generics meet originator benchmarks. A 2019 real-world study by the National Healthcare Security Administration (NHSA) confirmed no statistically significant differences in safety or efficacy between 14 generics and their originators
. Rising patient trust in generics further accelerates market substitution.
III. Domestic Pharma's Tailwinds: Policy Tailwinds and Industrial Upgrading
The vacuum left by imported drugs creates strategic advantages for Chinese players:
NCMP Rule Refinements
The 11th NCMP introduced "anti-price wars" measures, including cost transparency requirements and volume guarantees for established market leaders. This stabilizes revenue for compliant companies while discouraging predatory pricing
.
Innovation-Driven Growth
NCMP savings fund R&D: 80% of innovative drugs now secure reimbursement within two years of approval, reducing financial risks. Leading firms like Innovent Biologics and BeiGene leverage scale to maintain 50% gross margins despite pricing pressures
.
Industry Consolidation
The CR10 (top 10 firms' market share) surged from 35% in 2023 to 50% in 2025, concentrating resources in innovation-focused players
IV. Global Ambitions: From "Made in China" to "Invented in China"
Domestic pharma's internationalization is accelerating, driven by regulatory alignment and strategic partnerships:
Quality Benchmarking
Dozens of Chinese manufacturers now meet FDA and EMA standards. For example, Innovent's sintilimab and Hengrui's PD-1 inhibitors received U.S. approvals, signaling global recognition
.
Record-Breaking Licensing Deals
In 2025 alone, Chinese biotechs inked 93 overseas licensing agreements worth 85billion,withHengrui's12 billion pact with GSK setting a new milestone
. This reflects international pharma's appetite for China's cost-efficient innovation.
Diversified Globalization Strategies
Regional Expansion: Prioritizing Brazil, the Middle East/North Africa, and Eastern Europe for generics, while targeting Japan and Southeast Asia for complex therapies.
Model Evolution: Transitioning from "pure licensing" to co-development (e.g., BeiGene's collaboration with Novartis) and NewCo ventures (e.g., Hengrui's joint ventures with global funds)
Conclusion: From Survival to Supremacy
The withdrawal of imported generics is not a decline but a recalibration. As China tightens quality controls and rewards innovation, domestic players are transitioning from cost arbitrage to value creation. With 30% of global R&D pipelines now originating in China, the world's pharmaceutical hierarchy is being reshaped-one breakthrough at a time.
